Loading...

Intellectia LogoIntellectia
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. EQTY
EQTY logo

EQTY Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • AI Stock Picker
  • Swing Trading
  • SwingMax Portfolio
  • QuantAI Alpha Pick
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • Financial AI Agent
  • AI Screener
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
27.390
Open
27.390
VWAP
27.23
Vol
16.69K
Mkt Cap
--
Low
27.080
Amount
454.47K
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Events Timeline

No data

No data

News

Benzinga
9.0
01-15Benzinga
Becton, Dickinson and Company (BDX) Receives FDA Clearance for New Breast Biopsy System, Expected Market Launch in 2026
  • FDA Approval: The U.S. FDA granted clearance for Becton, Dickinson and Company's EnCor EnCompass Breast Biopsy and Tissue Removal System, expected to launch in early 2026, enhancing the biopsy experience across various imaging modalities and strengthening market competitiveness.
  • Stable Market Valuation: BDX maintains a market capitalization of $59.10 billion, with a 52-week stock range of $162.29 to $251.99, reflecting robust performance in the medical device sector and aligning with broader market trends, indicating investor confidence in future growth.
  • Positive Technical Indicators: BDX's Relative Strength Index (RSI) stands at 66.21, indicating neutral to bullish momentum, while a MACD of 2.94 suggests strong price momentum, potentially providing a favorable entry point for investors.
  • Earnings Forecast: Analysts project earnings per share of $2.82, down from $3.43 last year, with revenue slightly decreasing to $5.15 billion; however, the consensus Buy rating and an average price target of $245.93 reflect optimism about the company's future performance.
NASDAQ.COM
3.0
2025-07-24NASDAQ.COM
EQTY's Underlying Holdings Could Mean 10% Gain Potential
  • Kovitz Core Equity ETF Analysis: The Kovitz Core Equity ETF (EQTY) has an implied analyst target price of $28.13 per unit, indicating a potential upside of 10.10% from its current trading price of $25.55.

  • Notable Holdings and Analyst Targets: Key holdings like Fiserv Inc, Analog Devices Inc, and PPG Industries Inc show significant upside potential based on analyst targets, raising questions about the accuracy and optimism of these projections.

NASDAQ.COM
6.5
2025-05-22NASDAQ.COM
Analysts Expect 13% Upside For The Holdings of EQTY
  • Kovitz Core Equity ETF Analysis: The Kovitz Core Equity ETF (EQTY) has an implied analyst target price of $26.74 per unit, indicating a potential upside of 12.99% from its recent trading price of $23.67.

  • Notable Holdings with Upside Potential: Key holdings like Applied Materials (AMAT), AMENTUM HOLDINGS (AMTM), and Alphabet Inc (GOOGL) show significant upside potential based on analysts' target prices, suggesting optimism about their future performance.

Benzinga
9.5
2025-05-13Benzinga
Earnings Just Put Dan Loeb's Bets To The Test — Here's What Held Up
  • Earnings Insights: Dan Loeb's Third Point portfolio revealed mixed earnings results across various sectors, with Cinemark reducing its stake and reporting losses, while Corpay's sales missed estimates despite an EPS in line with consensus. Jacobs Solutions exceeded revenue expectations, while Primo Brands showed significant revenue growth but fell short of analyst estimates.

  • Stock Performance: Year-to-date performance varied among the companies, with Cinemark down 2.13%, Corpay up 3.32%, Jacobs down 4.57%, and Primo Brands increasing by 3.35%, reflecting differing market responses to their earnings reports and forecasts.

Benzinga
9.5
2025-04-10Benzinga
CarMax Accelerates Used Car Sales Growth, Despite Earnings Miss
  • Earnings Report Highlights: CarMax reported fourth-quarter sales of $6 billion, exceeding expectations, while retail used unit sales rose 6.2% year-over-year; however, earnings per share fell short of analyst estimates at 58 cents.

  • Future Outlook and Expansion Plans: The company plans to open six new store locations and four reconditioning/auction centers in fiscal year 2026, with projected capital expenditures of approximately $575 million due to deferred land purchases.

NASDAQ.COM
2.0
2025-04-01NASDAQ.COM
Kovitz Core Equity (EQTY) Shares Cross Above 200 DMA
  • 52 Week Range of EQTY: EQTY's stock has a 52-week low of $20.75 and a high of $25.33, with the last trade recorded at $23.41.

  • Author's Perspective: The opinions expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.

Wall Street analysts forecast EQTY stock price to rise
0 Analyst Rating
Wall Street analysts forecast EQTY stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for (EQTY) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
Current PE
NaN
Overvalued PE
Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
Current EV/EBITDA
NaN
Overvalued EV/EBITDA
Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
Current PS
NaN
Overvalued PS
Undervalued PS

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

What has the highest return rate right now?
Intellectia · 1020 candidates
Ticker
Name
Market Cap$
top bottom
BNB logo
BNB
BNB
89.64B
U logo
U
Union
1.03B
SOL logo
SOL
Solana
51.50B
VSN logo
VSN
Vision
187.46M
ETN logo
ETN
Electroneum
17.52M
DOGE logo
DOGE
Dogecoin
14.96B

Whales Holding EQTY

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is (EQTY) stock price today?

The current price of EQTY is 27.21 USD — it has decreased -0.84

What is (EQTY)'s business?

What is the price predicton of EQTY Stock?

Wall Street analysts forecast EQTY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EQTY is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is (EQTY)'s revenue for the last quarter?

revenue for the last quarter amounts to NaN USD, decreased

What is (EQTY)'s earnings per share (EPS) for the last quarter?

. EPS for the last quarter amounts to USD, decreased

How many employees does (EQTY). have?

(EQTY) has 0 emplpoyees as of March 05 2026.

What is (EQTY) market cap?

Today EQTY has the market capitalization of 0.00 USD.